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A framework for assessing the lifetime 
economic burden of congenital 
cytomegalovirus in the United States
Aaron Lucas1* , Anushua Sinha2, Karen B. Fowler3, Deirdre Mladsi1, Christine Barnett1, Salome Samant2 
and Laura Gibson4
Abstract 
Background: In the United States (US), congenital cytomegalovirus infection (cCMVi) is a major cause of permanent 
disabilities and the most common etiology of non-genetic sensorineural hearing loss. Evaluations of prevention strat-
egies will require estimates of the economic implications of cCMVi. We aimed to develop a conceptual framework to 
characterize the lifetime economic burden of cCMVi in the US and to use that framework to identify data gaps.
Methods: Direct health care, direct non-health care, indirect, and intangible costs associated with cCMVi were 
considered. An initial framework was constructed based on a targeted literature review, then validated and refined 
after consultation with experts. Published costs were identified and used to populate the framework. Data gaps were 
identified.
Results: The framework was constructed as a chance tree, categorizing clinical event occurrence to form patient 
profiles associated with distinct economic trajectories. The distribution and magnitude of costs varied by patient 
life stage, cCMVi diagnosis, severity of impairment, and developmental delays/disabilities. Published studies could 
not fully populate the framework. The literature best characterized direct health care costs associated with the birth 
period. Gaps existed for direct non-health care, indirect, and intangible costs, as well as health care costs associated 
with adult patients and those severely impaired.
Conclusions: Data gaps exist concerning the lifetime economic burden of cCMVi in the US. The conceptual frame-
work provides the basis for a research agenda to address these gaps. Understanding the full lifetime economic burden 
of cCMVi would inform clinicians, researchers, and policymakers, when assessing the value of cCMVi interventions.
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Background
Approximately 50% of people in the United States (US) 
have had human cytomegalovirus (CMV) infection by 
adulthood, as determined by positive serology [1]. The 
virus is spread by close contact with an infected person 
through saliva, urine, or other body fluids and also can be 
transmitted from a pregnant woman to her fetus during 
pregnancy—termed congenital CMV infection (cCMVi) 
[2]. In the US, cCMVi occurs in approximately 0.35% to 
0.67% of births [3].
About 25% of infants with cCMVi are born with abnor-
malities such as sensorineural hearing loss (SNHL), cho-
rioretinitis, jaundice, hepatitis, or microcephaly [2, 4]. 
While most infants are normal at birth, they may develop 
these abnormalities over time [2, 4]. Regardless of clini-
cal status at birth, approximately 18% of all children with 
cCMVi develop permanent neurodevelopmental delays 
or disabilities, often associated with SNHL or vision 
loss [4]. With cCMVi being the most common congeni-
tal infection in the US [5, 6], a significant need exists to 
reduce its burden.
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There are no US Food and Drug Administration 
(FDA)–approved drug treatments for cCMVi. Off-label 
use of the antiviral drug ganciclovir and its prodrug val-
ganciclovir are recommended for treating moderate to 
severe clinical manifestations of cCMVi in the neonatal 
period, with some clinicians using the antivirals in less 
severe cases [7]. However, a recent clinical trial demon-
strated only modest short-term efficacy for valganciclovir 
and spurred debate on duration of treatment [8]. Moreo-
ver, there are no FDA-approved vaccines or medications 
to prevent acquisition of CMV during pregnancy or 
mother-to-fetus transmission, but clinical trials are ongo-
ing [9].
As interventions to prevent the economic conse-
quences of cCMVi are developed, decision makers will 
require estimates of the economic burden of cCMVi 
to assess the cost-effectiveness of these new primary 
and secondary prevention efforts. Conceptual frame-
works have been used previously [10, 11] to evaluate 
the lifetime economic burden of congenital diseases and 
other conditions and to inform future research agendas 
(e.g., [10–12]).
With this in mind, the objectives of this study are (1) to 
develop a conceptual framework to characterize the life-
time economic burden of cCMVi in the US and (2) to use 
that framework to identify current data gaps for future 
research into the cost burden of cCMVi in the US.
Methods
The study’s objectives were addressed in two parts. First, 
an initial conceptual framework was constructed, then 
validated and refined in consultation with cCMV experts. 
Second, for each component of the conceptual frame-
work, costs were either identified from the published lit-
erature or flagged as data gaps.
This study focused only on cCMVi-specific costs. Out-
comes related to placental CMV infection and inflam-
mation, e.g., fetal loss, preterm delivery, and intrauterine 
growth restriction, were not included. These important 
birth outcomes have multiple causes [13, 14], and the 
fraction attributable to cCMVi is still being defined.
To develop the initial conceptual framework, an 
impact inventory of costs associated with cCMVi was 
constructed in accordance with current US methods 
guidance [15]. Published burden-of-illness studies in con-
genital diseases [10, 16] were used as models for adapting 
the impact inventory to cCMVi. The conceptual frame-
work, which was developed by a team of health econo-
mists, physicians, and clinical specialists and researchers, 
included the following types of condition-related costs, 
per best practices for health economic evaluations [15]:
• Direct health care costs (e.g.,  tests, physical therapy, 
occupational therapy).
• Direct non-health care costs (e.g.,  transportation, 
social services, education, special housing).
• Indirect costs (e.g., mortality- and morbidity-associ-
ated productivity loss for the patient, and caregiver).
• Intangible costs (e.g.,  increased anxiety or stress or 
other costs not typically monetized).
In addition, published literature on the classification 
of impairment, disability, and developmental delay was 
used to inform development of the framework [17–20]. 
The World Health Organization (WHO) in The Interna-
tional Classification of Functioning, Disability and Health 
for Children and Youth (ICF-CY) defines impairment as 
“a loss or abnormality in body structure or physiologi-
cal function (including mental functions)” [17; p229] 
citing examples of paralysis, cardiomyopathy, and deaf-
ness. Specific to cCMVi, examples include SNHL, vision 
loss, and neurological disorders, all of which may vary 
in severity. According to the WHO’s Early Childhood 
Development and Disability: A Discussion Paper, impair-
ments may result in developmental delays (“significant 
variation in the achievement of expected milestones for 
[an individual’s] actual or adjusted age” [21; p12]) or dis-
abilities (“negative aspects of the interaction between an 
individual [with a health condition] and that individual’s 
contextual factors [environmental and personal fac-
tors]” [21; p228]). According to the American Academy 
of Pediatrics [18], delays may occur in one or more areas 
of physical, language, intellectual, social, or emotional 
development and may be precursors to disabilities. If a 
developmental delay or disability is not detected early 
enough for targeted interventions, it may progress or 
become permanent [19, 20].
To capture the comprehensive cost of cCMVi, the 
impact inventory’s costs were examined for when (i.e., 
at what life stage) and how (e.g., degree of severity of 
cCMVi-related impairments) these costs would occur. 
For example, patients with cCMVi may have the bulk of 
one type of costs occur at one life stage (e.g., antiviral 
therapy during birth/infancy), while other types of costs 
may be incurred over a longer time span (e.g., SNHL 
management throughout childhood and into adulthood). 
Additionally, patients with severe impairment may use 
different resources (e.g., supplemental housing, and car-
egiver time) than patients with mild impairments. Differ-
ent trajectories for patients with cCMVi were constructed 
and organized in the form of a chance tree to illustrate 
the clinical and cost dependencies, and the chance tree 
was reviewed with experts in the field of cCMV, includ-
ing two medical epidemiologists (one as a co-author), a 
physician subspecialist (co-author), a ranking member 
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of a cCMV parent/family advocacy and support organi-
zation, a community hospital pharmacy director, and a 
C-Suite medical director.
To estimate the lifetime cost of cCMVi and identify 
relevant data gaps in the literature for estimating this 
cost, an initial targeted literature review was conducted 
by using keywords to search for US studies in PubMed 
and Google Scholar (e.g., “congenital CMV” AND [“eco-
nomic burden” OR “cost” OR “framework”]). Preliminary 
estimates were discussed with cCMV experts, and the lit-
erature was searched again using focused keywords. The 
literature searches were targeted to fill the trajectories 
illustrated by the conceptual framework. Tables of rel-
evant and recent cost estimates were compiled, and data 
gaps were identified.
Results
Conceptual framework
Key articles contributing insights to the development of 
the conceptual framework included cost-effectiveness 
analyses of interventions or vaccines for cCMVi in the US 
[22–25]; however, most of these analyses [22–24] relied 
on data for non-cCMVi-specific patient populations with 
disabilities that were published more than 25 years ago.
Few published economic studies of cCMVi–specific 
patient populations were identified. The literature review 
yielded four studies estimating direct health care costs 
for patients with cCMVi at birth [26, 27] or in the first 
year of life [27–29]. Three of the four studies [26–29] 
relied on the Kids’ Inpatient Database developed for the 
Healthcare Cost and Utilization Project [30]. The fourth 
study used two Truven Health Analytics MarketScan 
Research Databases (IBM Corp., Armonk, New York). 
No analyses were found that reported the costs of cCMVi 
after the first year.
The conceptual framework (Fig. 1) depicts key cCMVi 
profiles with economic trajectories corresponding to the 
life stages of the patient (i.e., birth/infancy, childhood/
adolescence, and adulthood). The framework assumes 
distinct but equivalent trajectories for diagnosed or 
undiagnosed cCMVi, although the chances of down-
stream consequences on a trajectory vary depending on 
diagnosis and any interventions. The framework differ-
entiates trajectories according to the degree of impair-
ment (severe versus mild to moderate) and whether 
Fig. 1 Conceptual framework chance tree for costs of congenital cytomegalovirus  infectiona. cCMVi indicates congenital cytomegalovirus 
infection. The chance nodes (probabilities) from cCMVi prevention strategies inform the costs of each trajectory. aIdentified costs for life stage 
categories are described in Tables 1, 2, 3. bBirth/infancy costs include costs during first year of life
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developmental delays or disabilities manifest as a result 
of impairment. These trajectories were differentiated 
because they represent substantially different cost pro-
files over a patient’s life. The framework is agnostic to 
the types of developmental delays or disabilities included 
within the categories of mild to moderate and severe 
impairment. However, for purposes of the literature 
review, assumptions were made regarding what these cat-
egories contain, as described in the results below.
The framework was populated with US-based cost esti-
mates for patients with cCMVi where available. Cost esti-
mates were inflated to 2018 US dollars (US $) using the 
medical care component of the Consumer Price Index 
[31].
Birth/infancy
Table  1 displays estimates of direct health care costs 
related to cCMVi in the first year of life [26–29]. The 
studies used to populate Table 1 differed in patient popu-
lation (all infants with diagnosed with cCMVi [27, 28] vs 
infants diagnosed with cCMVi and presence of specific 
symptoms at birth [26, 29]) and type of direct health care 
cost (all direct health care costs vs. hospitalization costs 
only [26–29]).
Clinical and economic drivers of the costs of cCMVi at 
birth and through the first year of life were found to be 
low birth weight [26, 29] and inpatient costs. In addition, 
inpatient costs were greater during the birth period than 
any other period during the first year of life [27, 29]. No 
direct non-health care, indirect, or intangible costs were 
included in the four studies. Because of this, the total 
economic burden of cCMVi during the first year of life 
could not be assessed.
Death
According to a review of studies of children with cCMVi, 
the cCMVi-related infant mortality rate for children with 
symptoms at birth ranges from 5 to 10% in the US [32]. 
Three of the above studies—Candrilli and Trantham [28], 
Lopez et  al. [29], and Inagaki et  al. [26]—found similar 
mortality rates in their analyses. Estimates of a long-term 
cCMVi-related mortality rate were not found in the lit-
erature. In addition to direct costs and patient (result-
ing from the loss of a productive lifetime) and caregiver 
indirect costs, early death of a child due to cCMVi may 
cause parental loss of productivity or income because of 
bereavement. Studies that estimate costs associated with 
premature mortality also may consider costs of living 
longer, although there are methodological and practical 
difficulties in doing so [33].
Severe impairment with permanent disability
The clinical manifestations of severe impairment result-
ing from cCMVi generally include microcephaly, seizures, 
and lack of motor function or language [34] and lead to 
permanent disability. Case reports [35, 36] and inter-
views with cCMV experts provided detailed descriptions 
of patients with severe impairment from cCMVi and 
the medical resources required to support them (Merck 
Sharp & Dohme Corp, data on file, January 23, 2018). The 
range of severe impairments described included autism-
like syndromes [35], learning disabilities, severe cogni-
tive impairment, and a range of disabilities necessitating 
special education [36]. Interviews with patient advocates 
and clinical leaders in the field of cCMV suggest that the 
lifetime costs of cCMVi may be largest among patients 
with severe impairment, but these patients may represent 
a heterogeneous group difficult to study.
Published cost estimates for patients with severe 
impairment resulting from cCMVi were not available. 
Congenital conditions, including Zika-associated micro-
cephaly and fetal alcohol spectrum disorder may be simi-
lar to the severe impairment resulting from cCMVi [37]. 
Published studies of these conditions estimate lifetime 
economic costs in the millions of dollars [38, 39]. The 
lifetime economic burden of severe impairment resulting 
from cCMVi may be of the same magnitude.
Lavelle et  al. [40] suggested that the economic bur-
den for patients with severe impairment resulting from 
cCMVi may be weighted heavily toward travel assistance, 
unpaid family–caregiver time, education support, and 
supplemental housing. Similarly, intangible costs may 
include requiring the family to adapt daily schedules to 
accommodate the combination of impairments. Accord-
ing to the member of a patient/family advocacy and 
support organization, families of severely affected chil-
dren may need to move to a different state that provides 
greater medical benefits aligned with the child’s needs.
Mild to moderate impairment with no developmental 
delay/disability
Although cCMVi-related impairments may not inter-
fere with long-term neurodevelopment, managing these 
abnormalities to maintain normal development may 
require health care resources. Estimates of the annual 
direct health care costs related to SNHL and vision loss 
from any cause range from about $1000 per patient 
(inflated from 2016 to 2018 US $) [23] for SNHL to 
almost $8000 per patient (inflated from 2013 to 2018 US 
$) [41] for vision loss (Table 2).
Health care resource use for SNHL may include hear-
ing device components, e.g., cochlear implants, which 
require surgery. Health care costs may be compounded 
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Table 1 Birth/infancy, diagnosed/intervention: direct health care costs related to cCMVi at birth/infancy
CCAE, Commercial Claims and Encounters; cCMVi, congenital cytomegalovirus infection; CPI, Consumer Price Index; geo, geometric; HIV, human immunodeficiency 
virus; ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification; ICD-10-CM, International Classification of Diseases, 10th Revision, Clinical 
Modification; KID, Kids’ Inpatient Database; SD, standard deviation; SE, standard error; US, United States
a Cost estimates are inflated to 2018 US $ using the medical care component of the CPI [31]. Meyers et al. and Candrilli and Trantham [28] were originally presented in 
2016 US $. Lopez et al. [29], and Inagaki et al. [26] were originally presented in 2012 US $
b Direct health care cost estimates exclude out-of-pocket costs
c Inagaki et al. [26] defined symptomatic cCMV disease as “cases with cCMV accompanied by one or more of the following ICD-9-CM codes (codes are diagnosis 
codes unless specified otherwise): thrombocytopenia (287.3, 287.4, 287.5, 776.1) or requirement for platelet transfusion (procedure code 99.05), petechiae (287.2, 
72.6,782.7), hepatomegaly (789.1), splenomegaly (289.51, 789.2), intrauterine growth restriction (764), hepatitis (070.9, 571.4, 571.8, 571.9, 573.1, 573.2, 573.3, 774.4), 
microcephaly (742.1) or other central nervous system involvement (331.3, 331.4, 742.2, 742.3, 742.4, 779.7), hearing loss (389.1, 389.2, 389.7, 389.8, 389.9, 794.15), or 
chorioretinitis (363.0, 363.1, 363.20).” [p2]
d Inagaki et al. [26] reported the geometric mean of total charges for patients with and without symptomatic cCMV disease. The cCMVi-related cost estimate was 
calculated as the difference between these two means
e Knowledge of a cCMVi diagnosis may affect the choice of delivery. Meyers et al. [27] did not report whether the mother had knowledge of a cCMVi diagnosis before 
labor. Meyers et al. [27] also reported the difference of mean costs between patients with and without cCMV disease. The population characteristics in the above table 
were used to define cCMV disease
f According to Lopez et al. [29], “Symptomatic cCMV-related conditions were defined using International Classification of Diseases, 9th Revision, codes as follows: 
microcephaly (742.1), hepatomegaly (789.1, 573.1), splenomegaly (789.2), thrombocytopenia (776.1, 287.3, 287.4, 287.5, 776.2), seizures (345, 779.0, 780.39), 
encephalitis (323, 058), other neurological symptoms (742), cerebral palsy (343), petechiae (772.6, 782.7), hearing loss (389, 315.34, 388.2) and chorioretinitis (363.0, 
363.1, 363.2, 363.3).” [p2]
g Lopez et al. [29] and Candrilli and Trantham [28] estimated hospitalization costs specifically related to symptomatic cCMVi
Cost component Cost  estimatea,b Cost estimate 
(uncertainty)
Population Data source Source
cCMVi-related total direct health care costs per patient
 Birth to < 1 year Mean: $61,056 SD: $177,404 At least one medical 
claim with a corre-
sponding diagnosis 
(i.e., ICD-9-CM code 
771.1 or 078.5; ICD-
10-CM code P35.1 or 
B25) and < 1 year of age 
on the first observed 
claim for cCMVi
MarketScan 
CCAE and 
Medicaid 
databases
Meyers et al. [27]
Cost per hospitalization
 Birth only Geo mean: $96,283 SE: $10,507 In-hospital birth with an 
ICD-9-CM code of 771.1 
in any diagnoses listed 
in the database and 
symptomatic  diseasec
KID Inagaki et al. [26]d
Mean, vaginal: $25,203
Mean, caesarian: $32,986
SD, vaginal: $96,443
SD, caesarian: $174,303
ICD-9-CM codes 771.1 
or 078.5 or ICD-10-CM 
code P35.1 or B25 
during birth-associated 
inpatient stay
MarketScan 
CCAE and 
Medicaid 
databases
Meyers et al. [27]e
 < 1 year (including 
birth)
Mean, < 1 year of age: 
$77,538
Mean, < 1 month of age: 
$93,371
SD, < 1 year of age: $5938
SD, < 1 month of age: 
$8732
Hospitalization in an 
infant < 1 year of age 
with an ICD-9-CM 
code for cCMVi (771.1), 
excluding those with 
codes for HIV (042) or 
transplant-related diag-
noses (transplant [V42], 
transplant complica-
tion [996.8], transplant 
operation [E87.80]) 
and a cCMV-related 
 conditionf
KID Lopez et al. [29]g
Mean: $107,744 SD: $182,461 A diagnosis of cCMVi 
(ICD-9-CM code 771.1) 
and < 1 year of age at 
admission
KID Candrilli and Trantham 
[28]g
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over time (e.g.,  cochlear implants typically need to be 
replaced as the patient ages) [42]. Direct non-health care 
costs (e.g., educational support for missed classes) and 
indirect costs (e.g., lost productivity for missed workdays) 
may be incurred [23]. Moreover, intangible costs related 
to undergoing surgery, including heightened anxiety and 
short-term decreases in quality of life, also may arise.
Mild to moderate impairment with developmental delay/
disability in childhood/adolescence
Although cost estimates for developmental delays and 
disabilities were not available in the literature for patients 
with cCMVi specifically, recent estimates for proxy con-
ditions, e.g., autism spectrum disorder (ASD), attention-
deficit/hyperactivity disorder, and cerebral palsy (CP), 
were available. Table  3 presents the annual condition-
related direct health care and non-health care costs for 
patients in childhood/adolescence with these proxy 
conditions. For patients in childhood/adolescence with 
ASD, annual condition-related direct health care and 
non-health care costs were roughly $4000 and $17,000 
per patient, respectively (inflated from 2011 to 2018 
US $) [40]. For patients in childhood/adolescence with 
CP with or without intellectual disability (ID), annual 
condition-related direct health care costs ranged from 
roughly $22,000 (CP without ID) to $62,000 (CP with co-
occurring ID) (inflated from 2005 to 2018 US $) [43].
The economic costs associated with developmental 
delays and disabilities may include managing significant 
learning, behavioral, or motor dysfunction [37, 44, 45]. 
Moreover, these patients may need special education, 
caregiver attention, or supplemental housing in addition 
to routine medical care [40, 46]. Interviews with cCMV 
experts suggested that parents of children with cCMVi 
exhibiting even mild developmental delays or disabilities 
may experience costs associated with increased anxiety, 
depression, or familial tension (Merck Sharp & Dohme 
Corp, data on file, January 23, 2018).
Permanent disability
Patients with cCMVi who experience developmental 
delays or disabilities in childhood/adolescence may pro-
gress into adulthood with permanent disabilities. Cost 
estimates of adults with disabilities resulting from cCMVi 
specifically were not found in the literature, but one 
study [47] of adult, non-elderly patients with disabilities 
reported an annual incremental direct health care cost of 
roughly $14,000 per year compared with similar patients 
Table 2 Childhood/adolescence and  adulthood, mild to  moderate impairment with  no  developmental delay/disability: 
condition-related annual direct health care costs
CPI, Consumer Price Index; ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification; MEPS, Medical Expenditure Panel Survey; N/A, not 
applicable; SNHL, sensorineural hearing loss; US, United States
a Cost estimates are inflated to 2018 US $ using the medical care component of the CPI [31]. Gantt et al. [23] and Wittenborn and Rein [41] were originally presented 
in 2016 and 2013 US $, respectively
b Direct health care cost estimates exclude out-of-pocket costs
c Gantt et al. [23] does not report the type/measure of the cost estimate provided. Cost estimate from Wittenborn and Rein [41] does not control for the presence of 
other vision-related conditions
d The lower bound provides the cost estimate for patients with mild to moderate hearing loss; the upper bound proves the cost estimate for patients with severe to 
profound hearing loss
Cost component Cost  estimatea,b Cost estimate 
(variability)
Population Data source Source
Direct health care costs related to SNHL
 First year hearing 
loss is identified
Assumed: $1946 to 
$2006c,d
None reported N/A Medicare reimburse-
ment rates applied 
to treatment 
algorithms for mild, 
moderate, and 
severe SNHL based 
on clinical opinion
Gantt et al. [23]
 < 6 year of age Assumed: $1921 to 
$1971c,d
 6–12 year of age Assumed: $1595 to 
$1682c,d
 13–17 year of age Assumed: $1585 to 
$1673c,d
 ≥ 18 years of age Assumed: $984c
Direct health care costs related to vision loss
 Blindness/vision 
loss
Total, per person: 
$7623
None reported Respondents with ICD-9-CM 
code 361 (no self-reported 
diabetes), 362 (no self-reported 
diabetes), 369, or 378
MEPS Wittenborn and Rein 
[41]
 Retinal disorders 
(without diabetes)
Total, per person: 
$4268
 Strabismus Total, per person: 
$2705
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Table 3 Childhood/adolescence and  adulthood, mild to  moderate impairment with  developmental delay/disability: 
condition-related annual direct health care and non-health care costs
ASD, autism spectrum disorder; CP, cerebral palsy; CPI, Consumer Price Index; ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification; ID, 
intellectual disability; MEPS, Medical Expenditure Panel Survey; NHIS, National Health Interview Survey; SD, standard deviation; US, United States
a Cost estimates are inflated to 2018 US dollars using the medical care component of the CPI [31]. Lavelle et al. [40], Kancherla et al. [43], and Mitra et al. [47] were 
originally presented in 2011, 2005, and 2004 US dollars, respectively
b Lavelle et al. [40] used the publicly available MEPS (2003-2008) linked to the NHIS (2001–2007) to estimate annual total health care expenditures incurred by 
children aged 3–17 years who responded affirmatively to the question, “Has a doctor or health care provider ever told you that [child’s name] has autism?” and by 
those in a corresponding control group. Health care utilization counted by the expenditures included all categories reported in MEPS, but out-of-pocket costs were 
taken from household payments only
c Condition-related cost estimates from Kancherla et al. [43] were calculated by taking the difference in costs for patients with the condition versus patients in the 
control group. Condition-related cost estimates from Mitra et al. [47] were calculated by taking the difference in costs for disabled patients versus non-disabled 
Cost component Cost  estimatea,b,c Cost estimate 
(variability)
Population Data source Source
Direct health care costs related to mild to moderate impairment with developmental delay/disability in childhood/adolescence
 Out of pocket Total, per person, ASD: 
$219
CI, ASD: −$7 to $359 Children 3–17 years of 
age with  ASDb
MEPS linked to the NHIS Lavelle et al. [40]
 Third-party payers Total, per person, ASD: 
$3629
CI, ASD: $1222 to $5118 Children 3–17 years of 
age with  ASDb
MEPS linked to the NHIS Lavelle et al. [40]
Total, per person, ID 
without CP: $22,788
Total, per person, CP 
without ID: $22,333
Total, per person, CP 
with ID: $61,837
Not  calculatedd Children < 19 y of 
age with CP using 
ICD-9-CM code 343.
xx with at least one 
inpatient or two 
outpatient visits that 
were > 29 days apart 
during the study 
period
Patients with a medi-
cally diagnosed ID 
(identified as one 
inpatient or one 
outpatient claim with 
an ICD-9-CM code of 
317.xx-319.xx)
MarketScan Medicaid 
Multi-State Database
Kancherla et al. [43]
Direct non-health care costs related to mild to moderate impairment with developmental delay/disability in childhood/adolescence
 Education costs Total, per person, ASD: 
$10,346
CI, ASD: $7925 to 
$12,522
Nationally representa-
tive panel of caregiv-
ers and parents of 
children 3–17 years of 
age who had a child 
diagnosed with  ASDe
Administered survey Lavelle et al. [40]
 Condition-related 
therapy and family-
coordinated services
Total, per person, ASD: 
$421
CI, ASD: −$91 to $1168 Nationally representa-
tive panel of caregiv-
ers and parents of 
children 3–17 years of 
age who had a child 
diagnosed with  ASDe
Administered survey Lavelle et al. [40]
 Unpaid caregiver time 
costs
Total, per person, ASD: 
$6115
CI, ASD: −$2009 to 
$14,342
Nationally representa-
tive panel of caregiv-
ers and parents of 
children 3–17 years of 
age who had a child 
diagnosed with  ASDe
Administered survey Lavelle et al. [40]
Direct health care costs related to permanent disability in adulthood
 Out of pocket Mean: $1477 SD: $2631 Adults 21–61 years of 
age with self-reported 
functional and cogni-
tive limitations
MEPS Mitra et al. [47]
 Third-party payers Mean: $12,773 SD: $38,874 Adults 21–61 years of 
age with self-reported 
functional and cogni-
tive limitations
MEPS Mitra et al. [47]
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without disabilities (Table 3, inflated from 2004 to 2018 
US $).
Discussion
Assessing the full economic burden of cCMVi is essen-
tial for estimating the economic value of primary and 
secondary interventions, e.g., screening, vaccination, and 
clinical management to prevent impairment and perma-
nent disabilities. Prior to this research, no comprehensive 
assessment of the lifetime economic burden of cCMVi 
had been presented in the published literature. This 
study developed a conceptual framework following cur-
rent US guidelines for health economic evaluations [15]. 
The conceptual framework was developed by a team of 
economists and clinical experts in cCMV and informed 
by published literature and guidance from stakeholders 
in the patient advocacy, hospital, health insurance, and 
public health fields. The framework was used to direct 
searches for published cost estimates for cCMVi and 
to identify key data gaps in populating the framework, 
of which many were identified (see Additional file  1: 
Table S1). The findings from this qualitative project pro-
vide the basis for a research agenda to address these gaps.
Although the conceptual framework identified an array 
of cost impacts relevant to the lifetime economic burden 
of cCMVi, research published to date has focused pri-
marily on direct health care costs during the first year of 
life. No published studies of direct non-health care, indi-
rect, and intangible costs were identified. No published 
work was found that addressed costs of severe impair-
ment resulting from cCMVi or costs for adult patients.
Some research suggests that cCMVi may result in con-
ditions similar to ASD and CP [35, 46], but no studies 
of the costs of these disorders in patients with cCMVi 
were identified. Authors of previous economic analyses 
for cCMVi interventions have considered the economic 
consequences of cCMVi but without having cCMVi-
specific costs to populate their models (e.g.,  [16, 22, 24] 
[non-US]). In two of these analyses [24] and Lawrence 
et  al. [22] cost estimates for ID, vision loss, and SNHL 
were added together in different combinations to reflect 
the heterogeneity of cCMVi outcomes. However, the 
total economic burden of patients with cCMVi may be 
compounded by each individual consequence of the 
infection [43].
To address data gaps pertaining to the lifetime eco-
nomic burden of cCMVi in the US, researchers have 
several potential resources, including health insurance 
claims databases (e.g.,  those maintained by IBM), pub-
licly available health surveys, disease registries (e.g.,  the 
National Congenital CMV Disease Registry), and par-
ent/family advocacy and support organizations (e.g., The 
National CMV Foundation). However, these data sources 
have limitations with regard to informing lifetime cost 
studies. For example, health insurance claims databases 
have a relatively restricted period of follow-up because 
of movement across plans (e.g.,  [48] suggest that 20% of 
commercially insured people in the US change insur-
ers annually). Therefore, distinguishing congenital and 
postnatal CMV infection may not be feasible in a health 
insurance claims database.
Disease registries have a period of follow-up that is 
likely to be much longer than a typical claims database. 
Registries also may offer data indicating direct and indi-
rect costs, although the data may not be collected sys-
tematically or be complete given that these registries’ 
missions may not refer explicitly to assessing the eco-
nomic burden of cCMVi (e.g., as in the National Congen-
ital CMV Disease Registry) [49].
Additional research using existing data sources may be 
valuable, but for cCMVi such sources may have limita-
tions that could make primary data collection studies or 
hybrid studies (i.e., complementing existing data sources 
with primary data collection) necessary to fill the gaps. 
For example, an inventory of cCMVi patient registries 
and the data they collect as well as their capacity to link 
to other data sources (e.g.,  US health insurance claims 
data) or expand the data collected (e.g.,  via a survey of 
registry participants or their families) would be informa-
tive to potential researchers. Linking data sources also 
may help researchers characterize the costs incurred 
before patients are diagnosed with cCMVi or associated 
with a delayed cCMVi diagnosis.
The methods used for this study were similar to those 
used in other disease areas (e.g., [10, 12]) and relied in 
part on targeted reviews of the published literature. 
Conducting a systematic literature review to develop 
patients. Condition-related cost estimates from Lavelle et al. [40] were taken from the reported regression-adjusted difference in costs for children with ASD compared 
with those for children without ASD
d Kancherla et al. [43] presented confidence intervals for the mean costs, but not for the condition-related differences reported here
e Lavelle et al. [40] used two surveys in 2011 to estimate non-health care expenditures from a nationally representative panel of caregivers and parents of children 
aged 3–17 years who have a child diagnosed with ASD and a corresponding control group. Reported tuition expenditures from all sources related to school were used 
to estimate education costs. Condition-related therapy and family-coordinated services include “treatments such as applied behavioral analysis, sensory integration, 
and communication therapies.” All other resources used to care for children are categorized as “family-coordinated services.” Unpaid caregiver time was estimated as 
the total time all caregivers in the child’s household spent on “activities such as coordinating their child’s therapies, homework help, and travel to appointments and 
activities during the previous 12 months.” Some out-of-pocket estimates for direct non-health care cost categories were reported as negative
Table 3 (continued)
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the conceptual framework would have introduced pre-
mature and potentially artificial restrictions. Instead, a 
more pragmatic, targeted literature review, customized 
to identify the studies most likely to reveal the potential 
lifetime cost of cCMVi was appropriate. The targeted lit-
erature reviews identified costs and data gaps in the exist-
ing published data characterizing the economic burden 
of cCMVi. The costs presented here may be useful for 
researchers quantifying the economic burden of cCMVi. 
However, because of the differences in study designs, 
caution should be taken when evaluating the costs of 
cCMVi presented in the literature.
The conceptual framework and resulting analysis pre-
sented here were developed using the current state of 
pertinent knowledge of cCMVi. The field of cCMVi 
research is growing, so the assumptions underlying the 
conceptual framework may evolve as researchers make 
new discoveries. As new primary and secondary inter-
ventions for cCMVi are developed, decision makers must 
assess the implications for cCMVi management guide-
lines. To evaluate accurately the cost-effectiveness and 
affordability of new interventions, comprehensive esti-
mates of the lifetime economic burden of cCMVi will be 
required.
Conclusions
This study has highlighted significant data gaps, par-
ticularly with respect to estimates of direct health and 
non-health care costs for adult patients and those with 
severe impairment, costs incurred prior to an established 
cCMVi diagnosis, and indirect and intangible costs. 
Existing data sources, e.g., health insurance claims data-
bases and registries, may provide valuable data, but new 
primary data collection studies are necessary to capture 
the range of costs associated with cCMVi. The conceptual 
framework developed in this study may serve as a helpful 
foundation for future research in estimating these costs.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1296 2-019-0189-0.
Additional file 1: Table S1. Gaps in cost components for estimating the 
economic burden of cCMVi.
Abbreviations
ASD: autism spectrum disorder; CCAE: Commercial Claims and Encounters; 
cCMV: congenital CMV; cCMVi: congenital CMV infection; CMV: cytomegalo-
virus; CP: cerebral palsy; CPI: Consumer Price Index; FDA: US Food and Drug 
Administration; HIV: human immunodeficiency virus; ICD-9-CM: International 
Classification of Diseases, 9th Revision, Clinical Modification; ICD-10-CM: Interna-
tional Classification of Diseases, 10th Revision, Clinical Modification; ICF-CY: Inter-
national Classification of Functioning, Disability and Health for Children and 
Youth; ID: intellectual disability; KID: Kids’ Inpatient Database; MEPS: Medical 
Expenditure Panel Survey; N/A: not applicable; NHIS: National Health Interview 
Survey; SD: standard deviation; SE: standard error; SNHL: sensorineural hearing 
loss; US: United States; WHO: World Health Organization.
Acknowledgements
None.
Authors’ contributions
Data were gathered and analyzed by all authors. The paper was written by AL, 
AS, KBF, DM, SS, and LG. All authors read and approved the final manuscript.
Funding
This study was supported by Merck Sharp & Dohme Corp., a subsidiary of 
Merck & Co., Inc., Kenilworth, NJ, USA.
Availability of data and materials
Not applicable.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
AS and SS are Merck employees. LG has received an honorarium from Merck 
for her contribution to this work. AL, KBF, CB, and DM have no competing 
interests.
Author details
1 RTI Health Solutions, 3040 Cornwallis Road, PO Box 12194, Research Triangle 
Park, NC 27709-2194, USA. 2 Center for Observational and Real-World Evidence 
(CORE), Merck & Co., Inc., Kenilworth, NJ, USA. 3 University of Alabama at Bir-
mingham, Birmingham, AL, USA. 4 University of Massachusetts Medical School, 
Worcester, MA, USA. 
Received: 8 May 2019   Accepted: 23 September 2019
References
 1. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the 
United States: the national health and nutrition examination surveys, 
1988–2004. Clin Infect Dis. 2010;50(11):1439–47.
 2. Centers for Disease Control and Prevention (CDC). Cytomegalovirus 
(CMV) and congenital CMV infection. 2018. http://www.cdc.gov/cmv/
index .html. Accessed 29 Oct 2018.
 3. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiol-
ogy of congenital cytomegalovirus (CMV) infection. Rev Med Viro. 
2007;17(4):253–76.
 4. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The “silent” 
global burden of congenital cytomegalovirus. Clin Microbiol Rev. 
2013;26(1):86–102.
 5. Thackeray R, Wright A, Chipman K. Congenital cytomegalovirus reference 
material: a content analysis of coverage and accuracy. Matern Child 
Health J. 2014;18(3):584–91.
 6. Bristow BN, O’Keefe KA, Shafir SC, Sorvillo FJ. Congenital cytomegalo-
virus mortality in the United States, 1990–2006. PLoS Negl Trop Dis. 
2011;5(4):e1140.
 7. Rawlinson WD, Boppana SB, Fowler KB, Kimberlin DW, Lazzarotto T, Alain 
S, et al. Congenital cytomegalovirus infection in pregnancy and the 
neonate: consensus recommendations for prevention, diagnosis, and 
therapy. Lancet Infect Dis. 2017;17(6):e177–8.
 8. Kimberlin DW, Jester PM, Sánchez PJ, Ahmed A, Arav-Boger R, Michaels 
MG, et al. National Institute of Allergy and Infectious Diseases Collabora-
tive Antiviral Study Group. Valganciclovir for symptomatic congenital 
cytomegalovirus disease. N Engl J Med. 2015;372(10):933–43.
 9. ClinicalTrials.gov. Search results for “congenital CMV”. https ://clini caltr ials.
gov/ct2/resul ts?term=conge nital +CMV&Searc h=Searc h. Accessed 29 
Oct 2018.
Page 10 of 10Lucas et al. Cost Eff Resour Alloc           (2019) 17:21 
 10. Popova S, Stade B, Lange S, Rehm J. A model for estimating the economic 
impact of fetal alcohol spectrum disorder. J Popul Ther Clin Pharmacol. 
2012;19(1):e51–65.
 11. Ericson L, Magnusson L, Hovstadius B. Societal costs of fetal alcohol 
syndrome in Sweden. Eur J Health Econ. 2017;18(5):575–85.
 12. Barnett CL, Mladsi D, Vredenburg M, Aggarwal K. Cost estimate of platelet 
transfusion in the United States for patients with chronic liver disease and 
associated thrombocytopenia undergoing elective procedures. J Med 
Econ. 2018;21(8):827–34.
 13. Goldenberg RL, Goepfert AR, Ramsey PS. Biochemical markers for the 
prediction of preterm birth. Am J Obstet Gynecol. 2005;192(5):S36–46.
 14. Resnick D, Manolagas S, Niwayama G, Fallon MD. Histogenesis, anatomy 
and physiology of bone. Diagnosis of bone and joint disorders. 4th ed. 
Philadelphia: WB Saunders Company; 2002. p. 648–54.
 15. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Rec-
ommendations for conduct, methodological practices, and reporting of 
cost-effectiveness analyses: second panel on cost-effectiveness in health 
and medicine. JAMA. 2016;316(10):1093–103.
 16. Halwachs-Baumann G, editor. Congenital cytomegalovirus infection: 
epidemiology, diagnosis, therapy. Springer Wien: New York; 2011.
 17. World Health Organization. International classification of functioning, 
disability, and health: children & youth version: ICF-CY. 2007. http://
apps.who.int/iris/bitst ream/handl e/10665 /43737 /97892 41547 321_eng.
pdf;jsess ionid =22327 C651B 903F6 92CC9 09D5C AE579 69?seque nce=1. 
Accessed 29 Oct 2018.
 18. American Academy of Pediatrics (AAP). Ages & stages. 2018. https ://www.
healt hychi ldren .org/engli sh/ages-stage s/pages /defau lt.aspx. Accessed 
29 Oct 2018.
 19. American Academy of Pediatrics (AAP). Language delays in toddlers: 
information for parents. 2011. https ://www.healt hychi ldren .org/Engli sh/
ages-stage s/toddl er/Pages /Langu age-Delay .aspx. Accessed 29 Oct 2018.
 20. Cheng ER, Palta M, Kotelchuck M, Poehlmann J, Witt WP. Cogni-
tive delay and behavior problems prior to school age. Pediatrics. 
2014;134(3):e749–57.
 21. World Health Organization (WHO). Early childhood development and dis-
ability: a discussion paper. 2012. http://apps.who.int/iris/bitst ream/handl 
e/10665 /75355 /?seque nce=1. Accessed 29 Oct 2018.
 22. Lawrence RS, Durch JS, Stratton KR, editors. Vaccines for the 21st century: 
a tool for decisionmaking. Washington, DC: National Academies Press; 
2000.
 23. Gantt S, Dionne F, Kozak FK, Goshen O, Goldfarb DM, Park AH, et al. Cost-
effectiveness of universal and targeted newborn screening for congenital 
cytomegalovirus infection. JAMA Pediatr. 2016;170(12):1173–80.
 24. Dempsey AF, Pangborn HM, Prosser LA. Cost-effectiveness of routine 
vaccination of adolescent females against cytomegalovirus. Vaccine. 
2012;30(27):4060–6.
 25. Williams EJ, Gray J, Luck S, Atkinson C, Embleton ND, Kadambari S, et al. 
First estimates of the potential cost and cost saving of protecting child-
hood hearing from damage caused by congenital CMV infection. Arch 
Dis Child Fetal Neonatal Ed. 2015;100(6):F501–6.
 26. Inagaki K, Blackshear C, Palmer A, Hobbs CV. Risk factors, geographic 
distribution, and healthcare burden of symptomatic congenital cytomeg-
alovirus infection in the United States: analysis of a nationally representa-
tive database, 2000–2012. J Pediatr. 2018;199(118–23):e1.
 27. Meyers J, Sinha A, Samant S, Candrilli S. The economic burden of con-
genital cytomegalovirus disease in the first year of life: a retrospective 
analysis of health insurance claims data in the United States. Clin Ther. 
2019;41(6):1040–56.
 28. Candrilli SD, Trantham L. The economic burden of congenital cyto-
megalovirus-related hospitalizations in the United States. Value Health. 
2017;20(9):A784–5.
 29. Lopez AS, Ortega-Sanchez IR, Bialek SR. Congenital cytomegalovirus-
related hospitalizations in infants < 1 year of age, United States, 
1997–2009. Pediatr Infect Dis J. 2014;33(11):1119–23.
 30. HCUP Databases. Healthcare Cost and Utilization Project. KID overview. 
2018. https ://www.hcup-us.ahrq.gov/kidov ervie w.jsp. Accessed 29 Oct 
2018.
 31. Bureau of Labor Statistics (BLS). Databases, tables & calculators by subject. 
https ://www.bls.gov/data. Accessed 4 Mar 2019.
 32. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neu-
rological and sensory sequelae and mortality associated with congenital 
cytomegalovirus infection. Rev Med Virol. 2007;17(5):355–63.
 33. Gold MR, Siegel JA, Russell LB, Weinstein, editors. Cost-effectiveness in 
health and medicine. New York: Oxford University Press; 1996.
 34. Luck SE, Wieringa JW, Blázquez-Gamero D, Henneke P, Schuster K, Butler 
K, et al. ESPID Congenital CMV Group Meeting, Leipzig 2015. Congenital 
cytomegalovirus: a European expert consensus statement on diagnosis 
and management. Pediatr Infect Dis J. 2017;36(12):1205–13.
 35. Sweeten TL, Posey DJ, McDougle CJ. Brief report: autistic disorder 
in three children with cytomegalovirus infection. J Autism Dev Dis. 
2004;34(5):583–6.
 36. Williamson WD, Desmond MM, LaFevers N, Taber LH, Catlin FI, Weaver TG. 
Symptomatic congenital cytomegalovirus: disorders of language, learn-
ing, and hearing. Am J Dis Child. 1982;136(10):902–5.
 37. Lanzieri TM, Leung J, Caviness AC, Chung W, Flores M, Blum P, et al. Long-
term outcomes of children with symptomatic congenital cytomegalovi-
rus disease. J Perinatol. 2017;37(7):875–80.
 38. Li R, Simmons KB, Bertolli J, Rivera-Garcia B, Cox S, Romero L, et al. Cost-
effectiveness of increasing access to contraception during the Zika virus 
outbreak, Puerto Rico, 2016. Emerg Infect Dis. 2017;23(1):74–82.
 39. Popova S, Stade B, Bekmuradov D, Lange S, Rehm J. What do we know 
about the economic impact of fetal alcohol spectrum disorder? A sys-
tematic literature review. Alcohol. 2011;46(4):490–7.
 40. Lavelle TA, Weinstein MC, Newhouse JP, Munir K, Kuhlthau KA, Prosser LA. 
Economic burden of childhood autism spectrum disorders. Pediatrics. 
2014;133(3):e520–9.
 41. Wittenborn JS, Rein DB. Cost of vision problems: the economic burden 
of vision loss and eye disorders in the United States. 2013. https ://www.
preve ntbli ndnes s.org/sites /defau lt/files /natio nal/docum ents/Econo 
mic%20Bur den%20of%20Vis ion%20Fin al%20Rep ort_13061 1_0.pdf. 
Accessed 29 Oct 2018.
 42. Wang JT, Wang AY, Psarros C, Da Cruz M. Rates of revision and device 
failure in cochlear implant surgery: a 30-year experience. Laryngoscope. 
2014;124(10):2393–9.
 43. Kancherla V, Amendah DD, Grosse SD, Yeargin-Allsopp M, Van Naarden 
Braun K. Medical expenditures attributable to cerebral palsy and intel-
lectual disability among Medicaid-enrolled children. Res Dev Disabil. 
2012;33(3):832–40.
 44. Alarcon A, Martinez-Biarge M, Cabañas F, Hernanz A, Quero J, Garcia-Alix 
A. Clinical, biochemical, and neuroimaging findings predict long-term 
neurodevelopmental outcome in symptomatic congenital cytomegalo-
virus infection. J Pediatr. 2013;163(3):828–34.
 45. Cameron NA, Gormley ME Jr, Deshpande S. Severity of disability in 
patients with cerebral palsy secondary to symptomatic congenital cyto-
megalovirus encephalopathy. J Pediatr Rehabil Med. 2013;6(4):239–42.
 46. Korndewal MJ, Oudesluys-Murphy AM, Kroes A, van der Sande MAB, de 
Melker HE, Vossen ACTM. Long-term impairment attributable to con-
genital cytomegalovirus infection: a retrospective cohort study. Dev Med 
Child Neurol. 2017;59(12):1261–8.
 47. Mitra S, Findley PA, Sambamoorthi U. Health care expenditures of living 
with a disability: total expenditures, out-of-pocket expenses, and burden, 
1996 to 2004. Arch Phys Med Rehabil. 2009;90(9):1532–40.
 48. Cunningham PJ, Kohn L. Health plan switching: choice or circumstance? 
Health Aff. 2000;19(3):158–64.
 49. Baylor College of Medicine. Congenital CMV disease research clinic & 
registry. https ://www.bcm.edu/depar tment s/pedia trics /secti ons-divis 
ions-cente rs/cmvre gistr y/. Accessed 14 Jan 2019.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
